By Lauren VanDenBoom

April 23, 2020

hc1 has announced an enhancement to that enables public health professionals and healthcare providers to now see at-a-glance if their county or Public Use Microdata Area (PUMA) is experiencing accelerating or decelerating COVID-19 infection rates.

The Local Risk Index (LRI) will provide actionable insights to healthcare and public health officials to prepare for peak COVID-19 viral activity 5 to 21 days in advance. This local insight helps leaders prepare for increase in local demand for COVID-19 care resources like ER visits, hospitalizations and ICU transfers.

Anonymized trending data from a coalition of more than 20,000 lab ordering locations supports the CV19 Lab Testing Dashboard’s LRI and visualizations of COVID-19 testing rates, positive and negative test results, and key demographic filters like age and gender down to the county and neighborhood (Public Use Microdata Area) level. 

With our nation in a historic battle to save lives and preserve our social and economic way of life, hc1 is channeling all of our energy, technology, and data assets to help local communities, public health officials, and healthcare organizations get in front of this wave.

“Partners across the country have told us health systems and public health officials need more timely and granular insight to better plan for and address the needs of the CV-19 pandemic,” said Brad Bostic, hc1 CEO. “hc1’s core business focuses on transforming lab data into personalized healthcare insights. Given our unique assets and capabilities, we mobilized our team and lab coalition partners to quickly deliver a critical component of national surveillance infrastructure that addresses these challenges.”

The CV19 Lab Testing Dashboard powered by hc1 is a free public health service for individuals directly involved with implementing policies and delivering care to mitigate the spread of COVID-19. Included are public health officials, government agencies and healthcare providers. Qualified individuals need only request access at

Previous Post The Double-Edged Sword of SARS-CoV-2 Antibody Testing
Next Post The hc1 Platform Delivers Unique COVID-19 Insights